Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
108 Million increase to outstanding shares today
What news?
Mary, welcome back and thank you for this post. Good news and Lori promising more communication is a huge plus!
As long as he is on the board of Directors he should be an insider. I know there are limited windows that insiders can sell in. I think there's a blackout period before and after financials but I don't recall how long that is.
OS seemed to stop growing for a while but the last few days it's been increasing some. It's at 815,991,809 now.
Thank you
Gangsta,
They filed a NT 4-K extension on 1-4-2021 that gives them 15 calendar days to release their financials. Does anyone know when Walthrup can start selling his shares now that he is no longer CEO? I assume he is still considered an insider so should be limited as to when he can sell. He's got a ton of stock.
LuckyBoy,
I don't have Twitter access can you copy the post here?
If I'm not mistaken Financials are due about now!!! Come on EVIO be on time!!!
to the,
Thank you for posting this link.
I had not seen this shareholder message. I'm glad they are sharing some information.
It's bee crazy high volume and big increase in available shares. When this note-holder gets done cashing in the PPS should pop up some, how much, who knows.
EVIO, Inc. Expands CDB Product Stability Studies Internationally
October 8, 2020
HENDERSON, NV / ACCESSWIRE / October 8, 2020 / EVIO, Inc. (the "Company" or "EVIO") (OTC PINK:EVIO), is proud to announce the launch of our first set of international accelerated cannabinoid shelf life & stability tests in conjunction with our subsidiary, Keystone Labs, in Alberta, Canada. This new and developing aspect of cannabis testing offers significant potential for EVIO to again be a leader in the rapidly expanding market of cannabis THC, CBD & Hemp testing.
This study was triggered by a deadline set by the British food regulators (FSA) for their new CBD food rules. These new regulations stipulate that after March 31, 2021, only products that have "submitted a valid application will be allowed to remain on the market," which includes product stability.
EVIO Labs CEO William Waldrop noted, "This developing need in the cannabis market creates a great opportunity for EVIO to get ahead of the competition with a process that has barriers to entry and requires meaningful specialization. Our geographic presence in key THC, CBD, and Hemp markets gives us a path for becoming a leader in this unique aspect testing, which we feel confident will become an expected requirement in the US and Canada. Getting ahead of this now will give us an early mover advantage on a process that offers EVIO significant revenue growth, in addition to notably improved margins."
EVIO Labs can now help USA based CBD companies meet more international requirements by facilitating accelerated stability tests for the purpose of international sales. EVIO will be implementing this testing service in all of its labs and marketing the new ability to help companies with this need.
National Initiatives
Since launching nationally targeted CBD and Hemp product marketing initiatives on the heels of the 2018 Farm Bill approval, the launch of our website www.hemptesting.com, and the explosion of the availability of CBD products, the Company has driven new revenue growth by testing hemp flower and a myriad of hemp and CBD manufactured products from around the US. The Company has created the Hemp and CBD Safety Panel test, focused on providing manufacturers and distributors a comprehensive suite of tests that gives clients the utmost confidence in the purity and potency of their products. The company anticipates both hemp and CBD trends to continue, further expanding EVIO's market position.
You all can thank me. I got tired of holding this stock so yesterday put sell in at $1.55 half what I bought for so of course it took off today!
AEMD is taking off, what's going on with this today?
Anybody have a clue what's causing the spike in volume and PPS today?
Fully understand, I wasn't trying to convince anyone to buy. It just makes sense to me that the license would be forfeited if the Lab is moved.
Just an FYI, this from the EVIO Website:
Effective today (6/22/2020), some of our Hemp and CBD testing panels and packages will be temporarily unavailable while we relocate our California facility to it’s new location.
Up nicely again today!
Nice uptick today so far!
Fourth Quarter & Fiscal Year End 2020 Investor Call
Jun 25, 2020 • 4:15pm EDT
Interested parties can register for the conference by navigating to http://dpregister.com/10145174. Please note that registered participants will receive their dial in number upon registration.
Interested parties without internet access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately one hour after the end of the call through July 2, 2020. The replay can be accessed by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10145174.
What's causing the PPS to fall after such good news?
Next week.
Hi Bill,
Thank you for contacting us.
Yes. We will give an update on this during our Q4 conference call and the press release. This should be during the week of June 22nd.
Kind regards,
Susan
I wrote Susan Noonan at AEMD and asked this question; see her response below.
Hello Susan,
As a stock holder I am curious as to what the status is for the Hemopurifier EFS? Is there any progress being made?
Aethlon received a "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA) to support the advancement of the Hemopurifier® for the treatment of cancer. In October 2019, the FDA approved Aethlon's Investigational Device Exemption (IDE) application to initiate an Early Feasibility Study (EFS) of the Hemopurifier® in patients with advanced head and neck cancer in combination with standard of care KEYTRUDA®. This EFS, which is the device equivalent of a phase 1 trial, will be a small single center, open label trial in 10 to 12 subjects.
Hi Bill,
Thank you for contacting us.
Yes. We will give an update on this during our Q4 conference call and the press release. This should be during the week of June 22nd.
Kind regards,
Susan
Well I'm on your side Monroe and I'd love this stocks PPS to more than double so I can get my money back out but the Time Magazine article was 6 years ago.
Moderators!
Huge Volume today, nice to see some upward movement yesterday and today. Nothing could be done for Mass. progress during the COD shutdown, hopefully good news coming soon!
GLTA
Thanks for all your posts Monroe1, nice to see some facts on here. All the bashing but obvious short positions gets tiring!
Current Open Positions at Evio Labs:
Berkeley, Ca
Client Services Representative
Location: Berkeley, CA
+ View details
Corporate Office
Accounts Payable Specialist
Location: Henderson, NV
+ View details
Inside Sales Representative
Location: Henderson, NV
+ View details
EVIO Labs MA
Laboratory Technician
Location: Framingham, MA
+ View details
Current Barrons - buy rating $1.75 Target price
https://www.barrons.com/quote/stock/us/ootc/evio/research-ratings
Another analyst grouping EVIO in the MAJOR Players category:
US Cannabis Testing Services Market to Surpass US$ 409.3 Million By 2027 – Coherent Market Insights
December 17, 2019 11:43 AM Eastern Standard Time
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the US Cannabis Testing Services Market was valued at US$ 127.7 million in 2019, and is expected to exhibit a CAGR of 15.7% over the forecast period (2019 – 2027).
• Major players operating in the US Cannabis Testing Services Market include SC Laboratories Inc., Eurofins Scientific, EVIO Labs, Praxis Laboratory, Agricore Laboratories, Steep Hill Labs, Inc., Digipath, Inc., Sequoia Analytical Labs, Fairbanks Analytical Testing LLC, Aurum Laboratories, LLC, Pure Analytics LLC, Gobi Labs, Cascadia Labs, Encore labs, PharmLabs LLC and Cann-a-Lab.
Contacts
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
An Industry Analyst
Arun Hegde
Corporate Sales, USA
Telephone: 1-888-689-0688
Email: Click to Email Arun Hegde
Web: https://www.gminsights.com/industry-analysis/us-cannabis-testing-market
Doesn't sound to me like this company is dead...
News
U.S. Cannabis Testing Market Demand and Projections to 2026 L Anresco, EVIO, Inc., Iron Laboratories, Pure Analytics LLC, Inc, Steep Hill, Inc.
As per estimates, U.S. cannabis testing market is likely to cross the USD 1.2 billion mark by 2026.
Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/4481
Top Key Players:
Anresco, CannaSafe, Collective Wellness of California (CW Analytical Laboratories), Digipath, Inc., EVIO, Inc., Iron Laboratories, Pure Analytics LLC, PSI Labs, SC Labs, Inc, Steep Hill, Inc.
Recent industry developments:
•In May 2019, EVIO, Inc. announced the strategic partnership with Gexin Analytics Labs to complete the buildout and operation of EVIO Labs Costa Mesa. This strategy assisted the company to deliver analytical testing services throughout California and strengthen its market position.
Just got on the EVIO website chat and asked a few questions.
Portland and Medford Oregon, Berkley CA, and Toronto Canada Labs are all open and taking orders. I asked about Mass. and she said Massachusetts deemed Cannabis non-essential which at least partially explains why it's not open.
Statement regarding Aethlon’s position with respect to the potential for use of the Hemopurifier as a countermeasure against the current coronavirus SARS-CoV-2 (COVID-19) outbreak
The Hemopurifier is an investigational device that has not yet received FDA approval for any indication. Aethlon continues to investigate the potential for the use of the Hemopurifier in viral diseases under an open Investigational Device Exemption (IDE) and our FDA Breakthrough Designation for “…the treatment of life-threatening glycosylated viruses that are not addressed with an approved therapy.” The Company currently has an open FDA approved Expanded Access Protocol for the treatment of Ebola infected patients in the U.S. and a corresponding HealthCanada approval in Canada.
Based on our studies to date, the Hemopurifier can potentially clear many viruses that are pathogenic in humans, including HCV, HIV and Ebola. We do have data suggesting that it could clear a closely related coronavirus (MERS).
We do not yet have access to materials from SARS-CoV-2 (the causative agent in COVID-19) for testing, but we are working on obtaining access to some of these materials.
We also do not know whether clearing SARS-CoV-2 from the blood, which is what the Hemopurifier is designed to do, would have a positive effect on this disease, which primarily targets the lung.
Even if effective, the Hemopurifier would only potentially be indicated in those patients with the most severe and life-threatening manifestations.
We will continue to disclose material progress in our investigation of the potential for the Hemopurifier in this and other indications.
Supporting an initiative set by the U.S. Department of Health and Human Services
Emerging pathogens pose a significant threat to mankind. Of the hundreds of viral pathogens known to be infectious to man, only a few are addressed with proven antiviral drug or vaccine therapies. Beyond the looming threat of bioterrorism, a proliferation of international travel, urban crowding and global warming is expected to accelerate the emergence of future pandemics. In response, the U.S. Department of Health and Human Services (HHS) has established an initiative to support platform technology medical countermeasures with broad-spectrum capabilities. Based on preclinical studies and human treatment experiences, the Aethlon Hemopurifier® defines this initiative.
Administered to individuals infected with Ebola, Hepatitis C and HIV
To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV). In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to Time Magazine naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."
Status of clinical studies
Beyond human treatment experiences, pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats. These include: Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection. Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus, which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919. In vitro studies of other viral threats are ongoing.
A lot of volume today...what's up?
I emailed William and asked him to let us know what he could about financials, Mass. opening, Canada, etc. He responded quickly with this.
We are working to get the 10K filed. It was ready to go 45 days ago, and the lender that was helping to cover the costs went dark during initial stages of COVID. I was able to obtain proceeds and have paid the auditor. So hopefully it will get filed soon.
WIll
William Waldrop
CEO
EVIO Inc. (OTCQB: EVIO)
God help us all. I'm guilty of catching the fallen knife much like Carter. Bought 263,157 shares yesterday at $0.019 to average down to $.095 with some shares as high as $1.85. I have way too much invested in this now. Just hoping something good happens soon! Real Soon!
Enough with the Home Depot slams, we get it! It's really old!!!
From what I read this filter does work for the Ebola virus but there are cheaper less invasive treatment for it now. It also seems to show great promise and is being tested for two types of cancer. So, why in the world don't they at least try to test it on the Corona Virus. Just a PR statement they are conducting tests on it would boost this stock price. did the SEC scare them that much?
SKY,
Just an FYI, having the virus once does not make you immune to it. In fact I've heard the second time you catch it is usually worse than the first time. Stay well!